It's difficult to find a pair of biotech giants that have performed better than Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) this year. Both have left broader equities well behind since 2023 started. It's not a coincidence that these two major players in the diabetes and obesity care market are crushing it. Sales of weight-loss medicines are projected to skyrocket through the end of the decade.

As the two leaders in this field, Novo Nordisk and Eli Lilly are already benefiting. Both stocks seem to have excellent prospects, but which one edges out the other? Let's find out.

Continue reading

Source Fool.com